On May 25, 2021, the American Society of Clinical Oncology (ASCO) is hosting a free, virtual roundtable focused on achieving equity in precision cancer care.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
In a continuation of their collaboration to increase clinical trial participation among patients from underrepresented racial and ethnic groups, the American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) today announced plans to test a research site assessment tool and implicit bias training program, both of which are designed to address one of the barriers to clinical trial participation: trials not routinely being offered by clinicians to eligible patients.
The Centers for Medicare & Medicaid Services (CMS) released part two of the Notice of Benefit and Payment Parameters for 2022 and Pharmacy Benefit Standards final rule (NBPP). The rule finalizes some of the standards in the proposed rule for states, exchanges, non-federal governmental plans, issuers in the individual and small-group markets (including those that participate in the federally facilitated exchange direct enrollment program), and web brokers.
The Centers for Medicare & Medicaid Services released the Fiscal Year (FY) 2022 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospital Rates Proposed Rule. The proposed rule would update the Medicare fee-for-service payment rates and policies for inpatient hospitals and long-term care hospitals for FY 2022. It also aims to enhance the health care workforce in rural and underserved communities, in addition to addressing gaps in health equity.
From April 12-16, U.S. members of the Association for Clinical Oncology (ASCO) participated in the 2021 ASCO Advocacy Summit, where 148 advocates from 44 states and the District of Columbia held 222 virtual meetings – the most ever held during an Advocacy Summit – with Members of Congress and staff to urge action on important policies to improve access to high-quality, equitable care for people with cancer.
On April 22, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen.
Today, the Association for Clinical Oncology (ASCO) presented Senators Richard Burr (R-NC) and Ben Cardin (D-MD) with the annual Congressional Champion for Cancer Care Award in recognition of their ongoing commitment to legislation that improves the environment for cancer research, oncology practice, and the quality of care for patients. The award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their cancer care teams.
The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Jasmine Kamboj, MD, for her exceptional contributions to advocacy efforts to improve cancer care and research. A current member of ASCO’s Health Equity Committee, Dr. Kamboj volunteered much of her time to advocate on behalf of cancer advocacy priorities that impact people with cancer and their cancer care teams.
On April 13, 2021, the Food and Drug Administration granted accelerated approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with locally advanced or metastatic urothelial cancer (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.
On Friday, April 9, ASCO and Friends of Cancer Research (Friends) co-hosted a live virtual event, which brought together experts from across the healthcare sector to discuss the recent release of the new ASCO-Friends recommendations for modernizing eligibility criteria to improve patient access and representation in cancer clinical trials. ASCO-Friends recommendations address five specific areas: treatment washout periods, concomitant medications, prior therapies, laboratory reference ranges and test intervals, and patient performance status.
The Association for Clinical Oncology (ASCO) applauds the proposed $9 billion funding increase for the National Institutes of Health (NIH) in President Biden’s budget request for Fiscal Year (FY) 2022. Such a significant proposed investment in biomedical research demonstrates a real commitment from the Administration to supporting the nation’s research infrastructure.
On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
As part of its ongoing efforts to increase the diversity of the oncology workforce, the American Society of Clinical Oncology (ASCO) is launching a new internship program for medical students from populations underrepresented in medicine (UIM)1, and today announced five medical schools across the country that have been selected to serve as hosts in the inaugural Oncology Summer Internship (OSI) program. The selected medical schools include: The Ohio State University; the University of Arizona Health Sciences College of Medicine – Tucson; the University of California San Francisco (UCSF); the University of Pittsburgh; and the University of Rochester.
On April 6, 2021, the Food and Drug Administration approved a new dosage regimen of 500 mg/m2 as a 120-minute intravenous infusion every two weeks (Q2W) for cetuximab (Erbitux, ImClone LLC) for patients with K-Ras wild-type, EGFR-expressing colorectal cancer (mCRC) or squamous cell carcinoma of the head and neck (SCCHN).
On March 31, 2021, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, sanofi-aventis U.S. LLC) in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.